08
Feb
2012
31
Jan
2012
Groove Biopharma, Inc.: Series B $6M
Posted in I - Series B, Q - 4Q11, R - NORTH WEST, X - Antiinfective, X - Fibrosis, X - Oncology, X - miRNA, XX - WA
Groove Biopharma (Seattle, WA) a development-stage biopharmaceutical company focused on microRNA therapeutics for cancer, fibrosis and infectious disease, closed a $6M Series B financing. Participants include Amgen Ventures, Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.
23
Jan
2012
Intuity Medical, Inc.: Series D $12M
Posted in I - Series D, Q - 3Q11, R - WEST, X - Device (Diabetes), X - Device (Diagnostic), XX - CA
Intuity Medical (Sunnyvale, CA) a clinical-stage diagnostic device company focused on all-in-one blood sample collection and glucose analysis, closed a $12M Series D financing, bringing the total round to $76M. Participants include Accuitive Medical Ventures, Investor Growth Capital, Thomas McNerney, Venrock, Versant Ventures and U.S. Venture Partners.
Thanx for your patience as we catch-up.
25
Oct
2011
Kythera Biopharmaceuticals, Inc.: Series D $37.4M
Posted in I - Series D, Q - 3Q11, R - WEST, X - Aesthetics, X - Dermatology, XX - CA
Kythera Biopharmaceuticals (Calabasas, CA) a clinical-stage biopharmaceutical company focused on aesthetic dermatology, closed a $37.4M Series D financing. Participants include Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Jafco Ventures, Invus Financial Advisors, BBT Capital Management, Altitude Life Science Ventures and Foley Ventures.
22
Jul
2011
27
Apr
2011
25
Oct
2010
29
Sep
2010
OpGen, Inc.: Series B $17M
Posted in I - Series B, Q - 3Q10, R - MID ATLANTIC, X - Device (Sequencing), XX - MD
OpGen (Gaithersburg, MD) a commercial-stage genomics device company focused on optical mapping combining strain typing and sequencing, closed a $17M Series B round financing. Participants include jVen Capital, CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical and Versant Ventures.
21
Sep
2010
Okairos, AG: Series B $20.8M
Posted in I - Series B, Q - 3Q10, R - INTERNATIONAL, X - HIV, X - Hepatitis C, X - Influenza, X - Malaria, X - Vaccines
Okairos (Switzerland) a clinical-stage biopharmaceutical company developing T-cell vaccines against infectious diseases such as malaria, HIV, hepatitis C and influenza, closed a $20.8M Series B financing. Participants include Versant Ventures, Boehringer Ingelheim Venture Fund, BioMedPartners, Life Science Partners and Novartis Venture Fund.
26
Jul
2010
Mirina Corp.: Series A $3.9M
Posted in I - Series A, Q - 2Q10, R - NORTH WEST, X - Oncology, X - RNAi, XX - WA
Mirina (Seattle, WA) a development-stage biotechnology company focused on miRNA therapeutics for oncology and metabolic disorders, closed a $3.9M Series A financing, bringing the total round to $7.5M. Participants include Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.
11
Jun
2010
14
May
2010
16
Apr
2010
Achaogen, Inc. : Series C $56M
Posted in I - Series C, Q - 2Q10, R - WEST, X - Antibacterial, X - MDR, XX - CA
Achaogen (San Francisco, CA) a clinical-stage a biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, closed a $56M Series C financing. Participants include Frazier Healthcare Ventures, Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and Wellcome Trust.
OnBioVC PARTNERS
-
